Brilacidin for diabetic foot wounds

Press Release: Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market Cellceutix Study Shows Brilacidin to Expedite Healing in Animal Model of Diabetic Foot Wounds Quote: Cellceutix Corporation (otcqb:CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model. As a small molecule mimetic of human host defense proteins, brilacidin has demonstrated antibacterial and tissue healing properties on barrier surfaces, such as skin and mucous membranes.

Press Release: Cellceutix Plans for Entry in Diabetic Foot Wound and Ulcer Market Cellceutix Study Shows Brilacidin to Expedite Healing in Animal Model of Diabetic Foot Wounds Quote: Cellceutix Corporation (otcqb:CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that its lead antibiotic, Brilacidin(TM), demonstrated visually convincing wound healing properties in a recently completed experiment in a diabetic rat model. As a small molecule mimetic of human host defense proteins, brilacidin has demonstrated antibacterial and tissue healing properties on barrier surfaces, such as skin and mucous membranes.

Original post:
Brilacidin for diabetic foot wounds